SCHEMBL14716255

SCHEMBL14716255

CC(C)(C)OC(=O)N1CCC(O)(COCc2ccccc2)CC1

nearest known ligand 0.58

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
TACR1 P25103 1/20 0.58
OPRD1 P41143 1/20 0.50
OPRK1 P41145 1/20 0.50
STS P08842 1/20 0.47
GPR119 Q8TDV5 3/20 0.46
TSHR P16473 2/20 0.46
ALOX15 P16050 1/20 0.46
ATM Q13315 1/20 0.46
KDM4E B2RXH2 1/20 0.45
PKM P14618 1/20 0.45
NAMPT P43490 1/20 0.45
ACHE P22303 1/20 0.44
MEN1 O00255 1/20 0.44
KMT2A Q03164 1/20 0.44
YAP1 P46937 1/20 0.43
DTYMK P23919 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL21644253 0.87 TACR1 (0.51) TACR1OPRD1OPRK1STSGPR119
SCHEMBL1446835 0.86 TACR1 (0.60) TACR1OPRD1OPRK1STSGPR119
SCHEMBL2951728 0.86 OPRD1 (0.53) TACR1OPRD1OPRK1STSGPR119
SCHEMBL14716117 0.85 TACR1 (0.56) TACR1OPRD1OPRK1STSGPR119
SCHEMBL1981994 0.85 TACR1 (0.56) TACR1OPRD1OPRK1STSGPR119
SCHEMBL5767042 0.85 TACR1 (0.56) TACR1OPRD1OPRK1STSGPR119
SCHEMBL14904456 0.85 TACR1 (0.56) TACR1OPRD1OPRK1STSGPR119
SCHEMBL1978811 0.84 TACR1 (0.55) TACR1OPRD1OPRK1STSGPR119
SCHEMBL16554179 0.84 TACR1 (0.55) TACR1OPRD1OPRK1STSGPR119
SCHEMBL3492937 0.84 MEN1 (0.51) TACR1OPRD1OPRK1STSGPR119

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8822688-B2 Imidazo[1,2-a]pyridine derivative ASTELLAS PHARMA INC. (JP) 2014-09-02 US disclosed
US-8822688-B2 Imidazo[1,2-a]pyridine derivative ASTELLAS PHARMA INC. (JP) 2014-09-02 US disclosed
US-8822688-B2 Imidazo[1,2-a]pyridine derivative ASTELLAS PHARMA INC. (JP) 2014-09-02 US disclosed
EP-2565194-A1 IMIDAZO[1,2-a]PYRIDINE DERIVATIVE Astellas Pharma Inc. (JP) 2013-03-06 EP disclosed
US-20130053363-A1 IMIDAZO[1,2-a]PYRIDINE DERIVATIVE ASTELLAS PHARMA INC. (JP) 2013-02-28 US disclosed
US-20130053363-A1 IMIDAZO[1,2-a]PYRIDINE DERIVATIVE ASTELLAS PHARMA INC. (JP) 2013-02-28 US disclosed
US-20130053363-A1 IMIDAZO[1,2-a]PYRIDINE DERIVATIVE ASTELLAS PHARMA INC. (JP) 2013-02-28 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130053363-A1 IMIDAZO[1,2-a]PYRIDINE DERIVATIVE PDE4B, PDE4A, PDE4C TACR1 2864/4885OPRD1 3693/4885OPRK1 4311/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.